Goldman Sachs’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-11,200
| Closed | -$916K | – | 6629 |
|
|
2021
Q3 | $916K | Hold |
11,200
| – | – | ﹤0.01% | 4814 |
|
|
2021
Q2 | $1.02M | Sell |
11,200
-4,800
| -30% | -$427K | ﹤0.01% | 4741 |
|
|
2021
Q1 | $1.37M | Buy |
+16,000
| New | +$1.44M | ﹤0.01% | 4360 |
|
|
2020
Q4 | – | Sell |
-30,000
| Closed | -$2.61M | – | 5634 |
|
|
2020
Q3 | $2.61M | Sell |
30,000
-1,200
| -4% | -$104K | ﹤0.01% | 3377 |
|
|
2020
Q2 | $2.73M | Buy |
31,200
+10,000
| +47% | +$863K | ﹤0.01% | 3238 |
|
|
2020
Q1 | $1.75M | Sell |
21,200
-28,800
| -58% | -$2.57M | ﹤0.01% | 3397 |
|
|
2019
Q4 | $4.73M | Sell |
50,000
-32,500
| -39% | -$2.92M | ﹤0.01% | 3011 |
|
|
2019
Q3 | $7.17M | Buy |
+82,500
| New | +$7.41M | ﹤0.01% | 2581 |
|
|
2018
Q2 | – | Sell |
-1,451
| Closed | -$105K | – | 5892 |
|
|
2018
Q1 | $105K | Sell |
1,451
-4,241
| -75% | -$323K | ﹤0.01% | 5267 |
|
|
2017
Q4 | $428K | Sell |
5,692
-6,584
| -54% | -$497K | ﹤0.01% | 4945 |
|
|
2017
Q3 | $944K | Buy |
12,276
+1,786
| +17% | +$135K | ﹤0.01% | 4621 |
|
|
2017
Q2 | $785K | Sell |
10,490
-229,115
| -96% | -$16.2M | ﹤0.01% | 4687 |
|
|
2017
Q1 | $15.9M | Sell |
239,605
-7,254
| -3% | -$483K | ﹤0.01% | 2053 |
|
|
2016
Q4 | $16.1M | Buy |
246,859
+218,624
| +774% | +$14.2M | ﹤0.01% | 2107 |
|
|
2016
Q3 | $2M | Buy |
28,235
+9,821
| +53% | +$716K | ﹤0.01% | 3832 |
|
|
2016
Q2 | $1.36M | Buy |
18,414
+6,473
| +54% | +$447K | ﹤0.01% | 3939 |
|
|
2016
Q1 | $775K | Sell |
11,941
-200,211
| -94% | -$13.6M | ﹤0.01% | 4318 |
|
|
2015
Q4 | $16.4M | Sell |
212,152
-133,808
| -39% | -$10.6M | 0.01% | 1895 |
|
|
2015
Q3 | $28.5M | Buy |
345,960
+321,408
| +1,309% | +$28.6M | 0.01% | 1462 |
|
|
2015
Q2 | $2.16M | Buy |
24,552
+5,245
| +27% | +$481K | ﹤0.01% | 3761 |
|
|
2015
Q1 | $1.71M | Sell |
19,307
-32,810
| -63% | -$2.91M | ﹤0.01% | 3950 |
|
|
2014
Q4 | $4.33M | Buy |
52,117
+6,473
| +14% | +$537K | ﹤0.01% | 3139 |
|
|
2014
Q3 | $3.85M | Sell |
45,644
-27,789
| -38% | -$2.25M | ﹤0.01% | 3278 |
|
|
2014
Q2 | $5.96M | Sell |
73,433
-41,403
| -36% | -$3.26M | ﹤0.01% | 2845 |
|
|
2014
Q1 | $8.75M | Sell |
114,836
-27,566
| -19% | -$2.01M | ﹤0.01% | 2493 |
|
|
2013
Q4 | $10.3M | Buy |
142,402
+23,436
| +20% | +$1.63M | ﹤0.01% | 2343 |
|
|
2013
Q3 | $8.18M | Buy |
118,966
+47,765
| +67% | +$3.16M | ﹤0.01% | 2444 |
|
|
2013
Q2 | $4.51M | Buy |
+71,201
| New | +$4.63M | ﹤0.01% | 2855 |
|
Other funds holding NVS
Goldman Sachs's NVS Position: Q1 2026 in Review
Goldman Sachs increased its Novartis (NVS) stake by 138% in Q1 2026, buying an estimated $579M and bringing the position to 6,525,771 shares worth $997M. The position accounts for 0.11% of the portfolio, ranked #170.
Goldman Sachs first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. 1,592 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Goldman Sachs held 6,525,771 shares of Novartis worth $997M as of Q1 2026.
- Goldman Sachs bought 3,780,327 Novartis shares in Q1 2026, an estimated $579M.
- Novartis made up 0.11% of Goldman Sachs's portfolio in Q1 2026, its #170 holding.
- Goldman Sachs first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
- 1,592 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.